Methods for Sample Quality Assessment
AssigneeSomaLogic Operating Co., Inc.
InventorsDavid Astling, Matthew Westacott, Daniel Drolet
Life of this patent
Estimating the term…
Abstract
Biomarkers, methods, devices, reagents, systems, and kits used to assess the quality of a sample collected from a subject are provided. Such biomarkers, methods, devices, reagents, systems, and kits may be useful in evaluating compliance with fasting protocols.
Claims94
A method of assessing quality of a sample collected from a subject comprising detecting the level of each of N biomarker proteins in the sample, wherein N is at least 2, and wherein at least 2 of the N biomarker proteins are selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH, wherein the sample is a plasma sample.
A method comprising:
- a) measuring the level of each of N biomarker proteins in a plasma sample from a subject, wherein N is at least 2, and wherein at least 2 of the N biomarker proteins are selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH;
- and
- b) identifying the sample as an analysis sample or negative sample based on the level of the N biomarker proteins;
- wherein the analysis sample is a sample that is suitable for use in one or more of the following:
- protein biomarker discovery analysis, protein expression level analysis, a diagnostic method or a prognostic method, and the negative sample is a sample that is not suitable for use as an analysis sample.
A method comprising:
- a) contacting a plasma sample from a subject with a set of capture reagents, wherein each capture reagent has affinity for a different biomarker protein of N biomarker proteins wherein N is at least 2, and wherein at least 2 of the N biomarker proteins are selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH;
- and
- b) measuring the level of each N biomarker protein with the set of capture reagents.
A method for comparing a plurality of samples collected from a plurality of subjects comprising detecting the level of each of N biomarker proteins in each of the plurality of samples, wherein N is at least 1, and wherein at least 1 of the N biomarker proteins are selected FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH, wherein the sample is a plasma sample.
A kit comprising N biomarker protein capture reagents, wherein N is at least 2, and wherein at least 2 of the capture reagents bind to proteins selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH.
A method comprising detecting a level of each of N biomarker proteins in a sample, wherein N is at least 1, and wherein at least 1 of the N biomarker proteins is selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH.
A method comprising detecting a level of each of at least 1, 2, 3, 4, 5, 6, or 7 biomarker proteins in a sample, wherein the biomarker proteins are selected from FGFP1, TMEDA, Glucagon, GIP, FABPL, Insulin, and PH.
Dependencies are inferred from the claim text.